Form 4: ALX Oncology CFO Granted 303,000 Stock Options

ALX Oncology Holdings Inc.'s Chief Financial Officer, Harish Shantharam, was granted 303,000 stock options with an exercise price of $1.48.

Summary

• Harish Shantharam, Chief Financial Officer of ALX Oncology Holdings Inc., acquired 303,000 stock options.
• The options have an exercise price of $1.48 per share.
• The grant date for these options is January 26, 2026.
• The options expire on January 25, 2036.
• The shares underlying the option will vest in 48 equal monthly installments, commencing on February 26, 2026.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive like the CFO is generally a positive sign, indicating management alignment with long-term shareholder interests and confidence in future growth. The 10b5-1 plan also adds transparency to the transaction.

Positives

• The grant of stock options to the CFO aligns management's incentives with shareholder value creation.
• The transaction was made under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary transaction, which enhances transparency.

Risks

• The value of the stock options is dependent on the future performance of ALX Oncology's stock price exceeding the exercise price of $1.48.
• Future stock price volatility could impact the realized value of these options for the reporting person.

Future Outlook

The grant of long-term stock options suggests a commitment to the company's future performance and growth, aligning the Chief Financial Officer's incentives with long-term shareholder value creation.

Industry Context

Executive equity grants are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key management personnel, particularly in companies focused on long-term drug development and commercialization. This practice helps align the interests of executives with those of shareholders over an extended period.

Comparison to Industry Standards

• The grant of stock options as part of executive compensation is a common practice across the biotechnology sector, similar to companies like Amgen or Gilead Sciences, which frequently use equity to incentivize leadership.
• A 4-year monthly vesting schedule (48 installments) is a typical industry standard for executive equity awards, designed to promote long-term retention and performance.
• The exercise price being set at the market price on the grant date (implied by a $0 option price for the derivative itself) is also standard for incentive stock options.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of management's interests with long-term stock performance. There is a standard dilution risk if options are exercised, which is typical for equity compensation.
• Management: Increased incentive to drive company performance and stock appreciation, directly linking personal financial outcomes to company success.

Next Steps

• The stock options will begin vesting in 48 equal monthly installments starting February 26, 2026.
• The CFO may exercise these options at the $1.48 strike price once they vest and if the stock price is above this level.

Key Dates

Recommendation

This Form 4 filing reports a routine grant of stock options to the CFO as part of their compensation package. While it signals management's long-term alignment, it does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should continue to hold based on existing fundamental analysis, as this filing alone is not a catalyst for a 'buy' or 'sell' decision.

Keywords

ALX Oncology, ALXO, Stock Options, CFO Compensation, Insider Trading, Form 4, Equity Grant, Executive Compensation, Biotechnology, Oncology